Heart diseases and stroke

Current Neurology and Neuroscience Reports

Volumn 6, Issue 1, 2006, Pages 23-27

  Sila, Cathy A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; AORTA ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; BLEEDING; BRAIN EMBOLISM; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE ASSOCIATION; ENDOVASCULAR SURGERY; FEASIBILITY STUDY; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL DECISION MAKING; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT INDICATION;

AORTA; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOMYOPATHIES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HEART ANEURYSM; HEART DISEASES; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 31544458934     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-996-0005-z     Document Type: Review

References (42)

1. Foulkes MA, Wolf PA, Price TR, et al.: The Stroke Data Bank: design, methods and baseline characteristics. Stroke 1988, 19:547-554.
2. Bogousslavsky J, Cachin C, Regli F, et al.: Cardiac sources of embolism and cerebral infarction, clinical consequences and vascular concomitants. Neurology 1991, 41:855-859.
3. Roquer J, Campello AR, Gomis M: Sex differences in first-ever acute stroke. Stroke 2003, 34:1581-1585.
4. Kittner SJ, Stern BJ, Wozniak M, et al.: Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Neurology 1998, 50:890-894.
5. Kolominsky-Rabas PL, Weber M, Gefeller O, et al.: Epidemiology of ischemic stroke subtypes according to TOAST criteria. Stroke 2001, 32:2735-0.
6. Broderick JP, Phillips SJ, O'Fallon WM, et al.: Relationship of cardiac disease to stroke occurrence, recurrence and mortality. Stroke 1992, 23:1250-1256.
7. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
8. Albers GW, Sherman DG, Gress DR, et al.: Stroke prevention in nonvalvular atrial fibrillation; a review of prospective randomized trials. Ann Neurol 1991, 30:511-518.
9. Singer DE, Albers GW, Dalen JE, et al.: Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:429-456.
10. Quality Standard Committee of the American Academy of Neurology: Practice Parameter: Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation. Neurology 1998, 51:671-673.
11. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2001, 38:1231-1266.
12. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
13. Sherman DG, Kim SG, Boop BS, et al.: Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management AFFIRM study. Arch Int Med 2005, 165:1185-1191.
14. Deplanque D, Corea F, Arquizan C, et al.: Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart 1999, 82:563-569.
15. Joint Commission on Accreditation of Healthcare Organizations: Standardized Stroke Measure Set. http://www.jcaho.org/dscc/dsc/performance+measures/ stroke+measure+set.htm. Accessed September 15, 2005.
16. SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293:690-698.
17. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633-638.
18. Hughes S: One arm of ACTIVE trial stopped as warfarin shows superior outcomes to clopidogrel plus aspirin in AF. Heartwire September 7,2005. http://www.theheart.org.
19. Hohnloser SH, Connolly SJ: Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003, 14:S60-S63.
20. Ostermayer SH, Reisman M, Kramer PH, et al.: Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation. J Am Coll Cardiol 2005, 46:9-14.
21. http://www.atritech.net
22. Cappato R, Calkins H, Chen SA, et al.: Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005, 111:1100-1105.
23. Tong DC, Bolger A, Albers GW: Incidence of transcranial Doppler detected microemboli in patients referred for echocardiography. Stroke 1994, 25:2138-2141.
24. Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovate during the first 10 decades of life. Mayo Clin Proc 1984, 59:17-20.
25. Lechat P, Mas JL, Lascault G, et al.: Prevalence of patent foramen ovatein patients with stroke. N Engl J Med 1988, 319:1148-1152.
26. Lynch JJ, Shuchard GH, Gross CM, Wann LS: Prevalence of right-to-left atrial shunting in a healthy population; detection by Valsalva, maneuver contrast echocardiography. Am J Cardiol 1984, 68:1478-1480.
27. Louie EK, Konstadt SN, Rao TL, Scanlon PJ: Transesophageal echocardiographic diagnosis of right to left shunting across the foramen ovate in adults without prior stroke. Am J Coll Cardiol 1993, 21:1231-1237.
28. Cabanes L, Mas JL, Cohen A, et al.: Atrial septal aneurysm and patent foramen ovate as risk factors for cryptogenic stroke in patients less than 55 years of age. Stroke 1993, 24:1865-1873.
29. Homma S, Sacco RL, DiTullio MR, et al., for the PFO in Cryptogenic Stroke Study (PICSS) Investigators: Effect of medical treatment in stroke patients with patent foramen ovate. Circulation 2002, 105:2625-2631.
30. Windecker S, Wahl A, Chatterjee T, et al.: Percutaneous closure of patent foramen ovate in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000, 101:893-898.
31. NMT Medical: ClosureI trial. http://www.nmtmedical.com/products/ci/pfo/index.htm. Accessed September 15, 2005.
32. Amplatzer Medical Professionals: RESPECT PFO trial. http://www.amplatzer.com/us/medical_professionals/respect_trial.html. Accessed September 15, 2005.
33. Cardia Inc: Cardia family of products. http://www.cardiainc.com/. Accessed September 15, 2005.
34. Maisel L: Patent foramen ovate closure devices: moving beyond equipoise. JAMA 2005, 294:366-369.
35. Messé SR, Cucchiara B, Luciano J, et al.: PFO management: meurologists vs cardiologists. Neurology 2005, 65:172-173.
36. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ: Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997, 29:1074-1080. Erratum in J Am Coll Cardiol 1998, 32:555.
37. Massie BM, Krol WF, Ammon SE, et al.: The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004, 10:101-112.
38. http://www.clinicaltrials.gov/ct/gui/show/NCT00041938
39. Baddour LM, Wilson WR, Bayer AS, et al.: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 2005, 111:3167-3184.
40. Chapot R, Houdart E, Saint-Maurice JP, et al.: Endovascular treatment of cerebral mycotic aneurysms. Radiology 2002, 222:389-396.
41. The French Study of Aortic Plaques in Stroke Group: Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996, 334:1216-1221.
42. Donnan GA, Davis SM, Jones EF, et al.: Aortic source of brain embolism. Curr Treat Options Cardiovasc Med 2003, 5:211-219.